Advertisement

Pharmacology of Anti-Asthma Xanthines

  • C. G. A. Persson
  • R. Pauwels
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 98)

Abstract

The xanthine drugs are clinically effective in asthma. In select patients they produce therapeutc effects which cannot be accomplished by other drugs, singly or in combination, however high the dosages. Hence, if we can learn more about the mode of action of theophylline, the major anti-asthma xanthine, we may gain new insights into the mechanisms of asthma. The pharmacology of anti-asthma xanthines remains a topical field for experimental and clinical research.

Keywords

Allergy Clin Immunol Allergen Challenge Acute Severe Asthma Oral Theophylline Antiasthma Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander MR, Dull WL, Kasik JE (1980) Treatment of chronic obstructive pulmonary disease with orally administered theophylline. JAMA 244: 2286–2290PubMedCrossRefGoogle Scholar
  2. Allard E (1904) Uber Theocinvergiftung. Arch Klin Med 80: 510–519Google Scholar
  3. Andersson PT, Persson CGA (1988) Developments in anti-asthma glucocorticoids. In: O’Donnell SR, Persson CGA (eds). Directions for New Antiasthma Drugs. Birkhauser, Basel; 239–260CrossRefGoogle Scholar
  4. Andersson KE, Johannesson N, Karlberg B, Persson CGA (1984) Increase in plasma free fatty acids and natriuresis by xanthines may reflect adenosine antagonism. Eur J Clin Pharmacol 26: 33–38PubMedCrossRefGoogle Scholar
  5. Andersson P, Brange C, Sonmark B, Stahre G, Erjefalt I, Wieslander E, Persson CGA (1985) Anti-anaphylactic and anti-inflammatory effects of xanthines in the lung. In: Andersson KE, Persson CGA (eds) Anti-asthma xanthines and adenosine. Amsterdam, Excerpta, pp 187–192Google Scholar
  6. Barclay J, Whiting B, Addis GJ (1982) The influence of theophylline on maximal response to salbutamol in severe chronic obstructive pulmonary disease. Eur J Clin Pharmacol 32: 389–393CrossRefGoogle Scholar
  7. Barnes PJ, Greening AP, Neville L, Timmers J, Poole GW (1982) Single-dose slow release aminophylline at night prevents nocturnal asthma. Lancet 1: 299–301PubMedCrossRefGoogle Scholar
  8. Bergstrand H (1985) Xanthines as phosphodiesterase inhibitors. In: Andersson KE, Persson CGA (eds) Antiasthma xanthines and adenosine. Amsterdam, Excerpta, pp 16–22Google Scholar
  9. Berthet J, Sutherland EN, Rail TW (1957) The assay of glucagon and epinephrine with use of liver homogenates. J Biol Chem 229: 351–357PubMedGoogle Scholar
  10. Boe J, Swedish Socity of Chest Medicine (1988) Salbutamoel in acute asthma–a multicenter study. Am Rev Respir Dis 137: 36AGoogle Scholar
  11. Brenner M, Berkowitz R, Marshall N, Strunk RC (1988) Need for theophylline in severe steroid-requiring asthmatics. Clin Allergy 18: 143–150PubMedCrossRefGoogle Scholar
  12. Cartier A, Lemaire I, L’Archeveque J, Ghezzo H, Martin RR, Malo JL (1986) Theophylline partially inhibits bronchoconstriction caused by inhaled histamine in subjects with asthma. J Allergy Clin Immunol 77: 570–575PubMedCrossRefGoogle Scholar
  13. Chapman KR, Bryant D, Marlin GE, Mitchell C, Ruffin R, Inouye T, Pedersen B, Koskinen S, Osen SS, Ringdal N, Willey RF, Formgren H, Persson G, Kallen A, Ljungholm K (1989) A placebo-controlled dose-response study of enprofylline in the maintenance therapy of asthma. Am Rev Respir Dis 139: 688–693PubMedGoogle Scholar
  14. Chrystyn H, Mulley BA, Peake MD (1988) Dose response relation to oral theophylline in severe chronic obstructive airways disease. Br Med J 297: 1506–1510CrossRefGoogle Scholar
  15. Clark H, Cushley MJ, Persson CGA, Holgate ST (1989) The protective effects of intravenous theophylline and enprofylline against histamine-and adenosine-5’- monophosphate-provoked bronchoconstriction: implications for the mechanisms of action of xanthine derivatives in asthma. Pulm Pharmacol 2: 147–154CrossRefGoogle Scholar
  16. Crescioli S, Spinazzi A, Paleari D, Pozzan M, Mapp CE, Fabbri LM (1988) Theophylline inhibits early and late asthmatic reactions induced by allergens in atopic subjects with asthma. Am Rev Respir Dis 137: A35Google Scholar
  17. Cushley MJ, Tattersfield AE, Holgate ST (1983) Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol 15: 161–166PubMedGoogle Scholar
  18. Dutoit J, Salome CM, Woolcock A J (1987) Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not. Am Rev Respir Dis 136: 1174–1178PubMedCrossRefGoogle Scholar
  19. Erjefält I, Persson CGA (1989) Inflammatory passage of plasma macromolecules into airway wall and lumen. Pulm Pharmacol 2: 93–102PubMedCrossRefGoogle Scholar
  20. Fabbri LM, Allessandri MV, De Marzo N, Zocca E, Paleari D (1986). Long-lasting protective effect of slow-release theophylline on asthma induced by ultrasonically nebulized distilled water. Ann Allergy 56: 171–175PubMedGoogle Scholar
  21. Fink G, Mittelman M, Shohat B, Spitzer SA (1987) Theophylline-induced alterations in cellular immunity in asthmatic patients. Clin Allergy 17: 316–321Google Scholar
  22. Finney M, Karlsson JA, Persson CGA (1985) Effects of bronchoconstrictors on a novel human small airway preparation. Br J Pharmacol 85: 29–37PubMedGoogle Scholar
  23. Fliuk RB, Easton PA, Anthonisen NR (1985) Responses to large doses of salbutamol and theophylline in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 132: 871–874Google Scholar
  24. Fredholm BB (1980) Are the actions of methylxanthines due to antagonism of adenosine? Trends Pharmacol Sci 1: 129–132CrossRefGoogle Scholar
  25. Guyatt GH, Townsend M, Pugsley O (1987) Bronchodilators in chronic airflow limitation. Am Rev Respir Dis 135: 1069–1074PubMedGoogle Scholar
  26. Harada H, Ishizaka A, Yonemaru M, Mallick AA, Hatherill JR, Zheng H, Lilly CM, O’Hanley PT (1989) The effects of aminophylline and pentoxifylline on multiple organ damage after escherichia coli sepsis. Am Rev Respir Dis 140: 974–980PubMedGoogle Scholar
  27. Ishizaki T, Minegishi A, Morishita M, Odaijma Y, Kanagawa S, Nagai T, Yamaguchi M (1988) Plasma catecholamine concentrations during a 72-hour aminophylline infusion in children with acute asthma. J Allergy Clin Immunology 82: 146–154CrossRefGoogle Scholar
  28. Jenne JW, Siever JR, Druz WS, Solano JV, Cohen SM, Sharp JT (1984) The effect of maintenance theophylline therapy on lung work in severe chronic obstructive pulmonary disease while standing and walking. Am Rev Respir Dis 130: 600–605PubMedGoogle Scholar
  29. Karlsson JA, Persson CGA (1981) Influence of tracheal contraction on relaxant effects in vitro of theophylline and isoprenaline. Br J Pharmacol 74: 73–79PubMedGoogle Scholar
  30. Kips J, Pauwels R, Van Der Straeten M (1989) Effect of theophylline on the endotoxin-induced airway inflammation and bronchial hyperresponsiveness. J Allergy Cl in ImmunolGoogle Scholar
  31. Kjellin G, Persson CGA (1985) Xanthine derivatives. In:Andersson K-E, Persson CGA (eds) Anti-asthma xanthines and adenosine. Excerpts, Amsterdam, pp 223–229Google Scholar
  32. Kröll F, Karlsson JA, Nilsson E, Ryrfeldt Å, Persson CGA (1990) Rapid clearance of xanthines from airway and pulmonary tissues. Am Rev Respir Dis 141: 1167–1171PubMedGoogle Scholar
  33. Lindenschmidt RC, Witschi HP (1985) Attenuation of pulmonary fibrosis in mice by aminophylline. Biochem Pharmacol 34: 4269–4273PubMedCrossRefGoogle Scholar
  34. Littenberg B (1988) Aminophylline treatment in severe, acute asthma. JAMA 259: 1678–1684PubMedCrossRefGoogle Scholar
  35. Ljungholm K, Kallen A, Persson CGA, Persson G (1990) The anti-asthma efficacy of xanthines added to regimens of non-glucocorticoid and glucocorticoid therapies. Eur Respir J (in press)Google Scholar
  36. Lundblad KA, Persson CGA (1988) The epithelium and the pharmacology of guinea-pig tracheal tone in vitro. Br J Pharmacol 93: 909–917PubMedGoogle Scholar
  37. Lunell E, Svedmyr N, Andersson KE, Persson CGA (1983) A novel broncholdilator xanthine apparently without antagonism and tremorogenic effect. Eur J Resp Dis 64: 333–339Google Scholar
  38. Lunell E, Andersson KE, Persson CGA, Svedmyr N (1984) Intravenous enprofylline in asthma patients. Eur J Resp Dis 65: 28–34Google Scholar
  39. Magnussen H, Reuss G, Jorres R (1987) Theophylline has a dose related effect on the airway response to inhaled histamine and methacholine in asthmatics. Am Rev Respir Dis 136: 1163–1167PubMedCrossRefGoogle Scholar
  40. Mann JS, Holgate ST (1985) Specific antagonism of adenosine induced bronchocon-striction in asthma by oral theophylline. Br J Clin Pharmacol 19: 85–92Google Scholar
  41. Mapp C, Boshetto P, Dal Veccho L, Crescioil S, De Marzo N, Paleari D, Fabbri LM (1987) Protective effect of antiasthma drugs on late asthmatic reactions and increased airway responsiveness induced by toluene diisocyanate in sensitized subjects. Am Rev Respir Dis 136: 1403–1407PubMedCrossRefGoogle Scholar
  42. Marquardt DL, Parker CN, Sullivan TJ (1978) Potentiation of mast-cell mediator release by adenosine. J Immunol 120: 871–878PubMedGoogle Scholar
  43. Mentzer RM, R, Berne RM (1975) Release of adenosine by hypoxic canine lung tissue and its possible role in pulmonary circulation. Am J Physiol 229: 1625–1631PubMedGoogle Scholar
  44. Murciano D, Aubier M, Lecocguic Y, Pariente R (1984) Effect of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med 311: 349–353PubMedCrossRefGoogle Scholar
  45. Naclerio RM, Bartenfelder D, Proud D, Togias AG, Meyers DA, Kagey Sobotka A, Norman PS, Lichtenstein LM (1986) Theophylline reduces histamine release during pollen-induced rhinitis. J Allergy Clin Immunol 78: 874–876PubMedCrossRefGoogle Scholar
  46. Nassif EG, Weinberger M, Thompson R, Huntley W (1981) The value of maintenance theophylline in steroid-dependent asthma. N Engl J 304: 71–75CrossRefGoogle Scholar
  47. Nielson CP, Crowley JJ, Cusak BJ, Vestal RE (1986) Therapeutic concentrations of theophylline and enprofylline potentiate catecholamine effects and inhibit leukocyte activation. J Allergy Clim Immunol 78: 660–667CrossRefGoogle Scholar
  48. O’Donnell SR, Erjefalt I, Persson CGA (1990) Early and late tracheobronchial plasma exudation by platelet activating factor administered to the airway mucosal surface in guinea-pigs: effect of WEB 2086 and enprofylline. J Pharmacol Exp Ther 254: 65–70PubMedGoogle Scholar
  49. Orange PP, Kaliner MA, Laraia PJ, Austen KF (1971) Immunological release of histamine and slow reacting substance of anaphylaxis from human lung II. Influence of cellular levels of cyclic AMP. Fed Proc 30: 1725–1729Google Scholar
  50. Passamonte PM, Martinez A J (1984) Effect of inhaled atropine or metaproterenol in patients with chronic airway obstruction and therapeutic serum theophylline levels. Chest 85: 610–615PubMedCrossRefGoogle Scholar
  51. Pauwels R, Van Renterghem D, Van Der Straeten M, Johannesson N, Persson CGA (1985) The effect of theophylline and enprofylline on allergen-induced broncho- constriction. J Allergy Clin Immunol 76: 583–590PubMedCrossRefGoogle Scholar
  52. Perruchoud AP, Yerger L, Abraham W (1984) Differential effects of aminophylline on the early and late antigen-induced bronchial obstruction in allergic sheep. Respiration 46: 44Google Scholar
  53. Persson CGA (1982) Universal adenosine receptor antagonism is neither necessary nor desirable with xanthine antiasthmatics. Med Hypoth 8: 515–526CrossRefGoogle Scholar
  54. Persson CGA (1983) The profile of action of enprofylline or why adenosine antagonism seems less desirable with xanthine antiasthmatics. In: Morley J, Rainsford KD (eds) Pharmacology of asthma. Birkhauser, Basel, pp 115–129Google Scholar
  55. Persson CGA (1985a) On the medical history of xanthines and other remedies for asthma: a tribute to HH Salter. Thorax 40: 881–886PubMedCrossRefGoogle Scholar
  56. Persson CGA (1985b) Subdivision of xanthines. In: Andersson KE, Persson CGA (eds) Anti-asthma xanthines and adenosine. Excerpta, Amsterdam, pp 23–40Google Scholar
  57. Persson CGA (1986) Development of safer xanthine drugs for treatment of obstructive airway disease. J Allergy Clin Immunol 78: 817–824PubMedCrossRefGoogle Scholar
  58. Persson CGA (1988) Xanthines as airway antiinflammatory drugs. J Allergy Clin Immunol 81: 615–617PubMedCrossRefGoogle Scholar
  59. Persson CG A (1990a) On the medical history of asthma and rhinitis. In: Mygind N, Pipkorn U, Dahl R (eds) Rhinitis and asthma. Simliarities and differences. Munksgaard, Copenhagen, pp 9–21Google Scholar
  60. Persson CG A (1990b) Exudative indices in airways inflammation. In: Persson CG A, Brattsand R, Laitinen L, Venge P (eds) Inflammatory indices in chronic bronchitis. Birkhäuser, Basel 243–256Google Scholar
  61. Persson CGA, Erjefält I (1982) Seizure activity in animals given enprofylline and theophylline, two xanthines with partly different mechanisms of action. Arch Int Pharmacodyn Ther 258: 267–282PubMedGoogle Scholar
  62. Persson CGA, Gustafsson B (1986) Tracheal relaxation of combinations between xanthines and between a β2-receptor agonist and xanthines. Lung 164: 33–40PubMedCrossRefGoogle Scholar
  63. Persson CGA, Karlsson JA (1987) In vitro responses to bronchodilator durgs. In: Jenne JW, Murphy S (eds) Drug therapy for asthma. Research and clinical practice. Dekker, New York, pp 129–176Google Scholar
  64. Persson CGA, Kjellin G (1981) Enprofylline, a principally new antiasthmatic xanthine. Acta Pharmacol Toxicol 49: 313–316CrossRefGoogle Scholar
  65. Persson CGA, Ekman M, Erjefält I (1979) Vascular antipermeability effects of β-receptor antagonist and theophylline in the lung. Acta Pharmacol Toxicol 44: 216–220CrossRefGoogle Scholar
  66. Persson CGA, Erjefält I, Andersson P (1986a) Leakage of macromoleculs from guinea-pig tracheobronchial microcirculation. Effects of allergen, leukotrienes, tachykinins, and antiasthma durgs. Acta Physiol Scand 127: 95–104Google Scholar
  67. Persson CGA, Andersson KE, Kjellin G (1986b) Effects of enprofylline and theophylline may show the role of adenosine. Life Sci 38: 1057–1072PubMedCrossRefGoogle Scholar
  68. Persson CGA, Erjefält I, Gustafasson B (1988) Xanthines - symptomatic or prophylactic in asthma? In: O’Donnel SR, Persson CGA (eds) Direction for new anti-asthma drugs. Birkhäuser, Basel, pp 137–155CrossRefGoogle Scholar
  69. Pollock J, Kiechel F, Cooper D, Weinberger M (1977) Relationship of serum theophylline concentration to inhibition of exercise-induced bronchospasm and comparison with cromolyn. Pediatrics 60: 840–844PubMedGoogle Scholar
  70. Racineaux JL, Troussier J, Turcant J, Tuchais E, Allain P (1981) Comparison of bronchodilation effects of sablutanol and theophylline. Bull Eur Physiopathol Respir 17: 799–806Google Scholar
  71. Ruffin R, Bryant D, Burdon J, Marlin G, Mitchell C, O’Hehir R, Wilson J, Woolocock A, Webb S (1988) Comarison of the effects of nebuilzed terbutaline with intravenous enprofylline in patients with acute asthma. Chest 93: 510–514PubMedCrossRefGoogle Scholar
  72. Schmedeberg O (1905) Uber die Anwendung des Theophyllins als Diuretikum. Dtsch Arch Klin Med 82: 395–408Google Scholar
  73. Snyder SH (1981) Adenosine receptors and the actions of methylxanhines. Trends Neurosci 4: 242–244CrossRefGoogle Scholar
  74. Sutton PP, Pavia D, Bateman JRM, Clarke SW (1981) The effect of oral aminophylline on lung mucociliary clearance in man. Chest 80 (suppl): 889–892PubMedGoogle Scholar
  75. Taylor DR, Buick B, Kinney C, Lowry RC, McDevitt DG (1985) The efficacy of orally administered theophylline, inhaled salbutamol, and a combinaion of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis 131: 747–751PubMedGoogle Scholar
  76. Ther L, Maschaweck R, Hergott J (1957) Antagonismus zwischen Adenosine und Methylxanthinen am Reizleitungssystem des Herzens. Arch Exp Pathol Pharmacol 231: 586–601CrossRefGoogle Scholar
  77. Torphy T (1988) Action of mediators on airway smooth muscle: Functional antagonism as a mechanism for bronchodilator drugs. In: O’Donnell SR, Persson CGA (eds) Directions for new antiasthma drugs. Birkhauser, Basel, pp 37–54CrossRefGoogle Scholar
  78. Vilsvik JS, Persson CGA, Amundsen T et al. (1990) Comparison between theophylline and an adenosine non-blocking xanthine in acute asthma. Eur Respir J 3: 27–32PubMedGoogle Scholar
  79. Weinberger M (1984) Pharmacology and therapeutic use of theophylline. J Allergy Clin Immunol 73: 525–540PubMedCrossRefGoogle Scholar
  80. Welsh CH, Lien D, Worthen GS, Veil JV (1988) Pentoxifylline decreases endotoxin- induced pulmonary neutrophil sequestration and extravascular protein accumulation if the dog. Am Rev Respir Dis 138: 1106–1114PubMedGoogle Scholar
  81. Welton AF (1980) Regulatory role of adenosine in antigen-induced histamine-release from the lung tissue of actively sensitized guinea-pigs. Biochem Pharmacol 29: 1085–1092PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • C. G. A. Persson
  • R. Pauwels

There are no affiliations available

Personalised recommendations